Publicacións en colaboración con investigadores/as de Hospital Universitario La Paz (42)

2024

  1. Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial

    The Lancet Infectious Diseases, Vol. 24, Núm. 4, pp. 375-385

  2. Prevalence and Phenotypic Susceptibility to Doravirine of the HIV-1 Reverse Transcriptase V106I Polymorphism in B and Non-B Subtypes

    Journal of Infectious Diseases, Vol. 229, Núm. 6, pp. 1796-1802

2023

  1. Adult T-cell leukemia/lymphoma in HTLV-1 non-endemic regions

    Journal of Clinical Virology, Vol. 167

  2. Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver

    Revista Espanola de Enfermedades Digestivas, Vol. 115, Núm. 3, pp. 128-132

  3. Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 2, pp. 150-162

  4. Systematic influenza screening in cardiac intensive care units during the influenza season: A prospective study in Spain

    International Journal of Infectious Diseases, Vol. 136, pp. 37-42

  5. Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe

    Clinical Infectious Diseases, Vol. 76, Núm. 9, pp. 1628-1635

  6. Transmitted drug resistance to antiretroviral drugs in Spain during the period 2019–2021

    Journal of Medical Virology, Vol. 95, Núm. 12

2021

  1. Hepatitis C reflex testing in Spain in 2019: A story of success

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 39, Núm. 3, pp. 119-126

  2. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study

    The Lancet Infectious Diseases, Vol. 21, Núm. 6, pp. 783-792

  3. Spread of a SARS-CoV-2 variant through Europe in the summer of 2020

    Nature, Vol. 595, Núm. 7869, pp. 707-712

  4. The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant

    Nature Genetics, Vol. 53, Núm. 10, pp. 1405-1414

2020

  1. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain

    Clinical Microbiology and Infection, Vol. 26, Núm. 11, pp. 1525-1536

  2. GEHEP 010 study: Prevalence and distribution of hepatitis B virus genotypes in Spain (2000–2016)

    Journal of Infection, Vol. 81, Núm. 4, pp. 600-606

  3. Hospital admissions in individuals with HTLV-1 infection in Spain

    AIDS, Vol. 34, Núm. 7, pp. 1019-1027

  4. The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations

    The Journal of antimicrobial chemotherapy, Vol. 75, Núm. 5, pp. 1294-1300

2019

  1. Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain

    Journal of Antimicrobial Chemotherapy, Vol. 74, Núm. 5, pp. 1357-1362

  2. Clinical presentation of individuals with human T-cell leukemia virus type-1 infection in Spain

    Open Forum Infectious Diseases, Vol. 6, Núm. 2

  3. Diagnosis of hepatitis C virus infection in Spain: An opportunity to improve

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 4, pp. 231-238

  4. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world

    Journal of Hepatology, Vol. 71, Núm. 5, pp. 876-888